Literature DB >> 32101519

Continuous renal replacement therapy in critically ill patients with acute on chronic liver failure and acute kidney injury: A retrospective cohort study
.

Ivan E Saraiva, Victor M Ortiz-Soriano, Xiaonan Mei, Fabiola G Gianella, Winnie Sheu Woc, Rodrigo Zamudio, Andrew Kelly, Meera Gupta, Alla Y Grigorian, Javier A Neyra.   

Abstract

BACKGROUND: Incident acute kidney injury (AKI) in critically ill patients with acute on chronic liver failure (ACLF) is associated with poor prognosis. The role of continuous renal replacement therapy (CRRT) is not well established for patients with ACLF and AKI.
MATERIALS AND METHODS: We conducted a retrospective cohort study to examine clinical outcomes in 66 patients with ACLF and AKI requiring CRRT.
RESULTS: All-cause hospital mortality was 89.4%. Five (7.6%) patients were listed for liver transplantation, of whom 1 (1.5%) was eventually subjected to transplantation. Etiology of AKI included type 1 hepatorenal syndrome (HRS) with or without some degree of acute tubular necrosis (ATN) in 20 (30.3%) patients, and primarily ATN in 46 (69.7%) patients. When evaluated at the time of CRRT initiation, Child-Pugh-Turcotte (CPT) and Model for End-stage Liver Disease (MELD) (area under the receiver operating characteristics curve (AUROC) 0.67 for both) had fair performance for prediction of mortality, whereas Sequential Organ Failure Assessment (SOFA) and Chronic Liver Failure (CLIF)-SOFA performed better for the prediction of mortality (AUROC 0.87 for both). SOFA and CLIF-SOFA also performed well when determined at the time of ICU admission (AUROC 0.86 and 0.85, respectively). Etiology of liver disease or AKI did not influence prognosis.
CONCLUSION: Critically ill patients with ACLF and AKI requiring CRRT have poor hospital survival, even with provision of extracorporeal support therapy. SOFA and CLIF-SOFA are good prognostic tools of mortality in this susceptible population.
.

Entities:  

Year:  2020        PMID: 32101519     DOI: 10.5414/CN109983

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  'First week' is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure.

Authors:  Ashok Choudhury; Rajan Vijayaraghavan; Rakhi Maiwall; Manoj Kumar; Zhongping Duan; Chen Yu; Saeed Sadiq Hamid; Wasim Jafri; Amna Subhan Butt; Harshad Devarbhavi; Qin Ning; Ke Ma; Soek-Siam Tan; Akash Shukla; Radhakrishna Dhiman; Ajay Duseja; Sunil Taneja; C E Eapen; Ashish Goel; Sombat Treeprasertsuk; Mamun Al-Mahtab; Hasmik Ghazinyan; Dong Joon Kim; Manoj K Sahu; Guan Huei Lee; Laurentius A Lesmana; Rinaldi Cosmas Lesmana; Samir Shah; Zaigham Abbas; Jose D Sollano; P N Rao; Anand Kulkarni; Gamal Shiha; Ananta Shrestha; AKadir Dokmeci; Man Fung Yuen; Diana Alcantara Payawal; Kemal Fariz Kalista; V G Mohan Prasad; George K Lau; Fazal Karim; Priyanka Jain; Guresh Kumar; Vinod Arora; Viniyendra Pamecha; Piyush Sinha; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-10-04       Impact factor: 6.047

2.  Acute Kidney Injury Treatment in Decompensated Cirrhosis: A Focus on Kidney Replacement Therapy.

Authors:  Andrew S Allegretti
Journal:  Kidney Med       Date:  2020-12-05

Review 3.  Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.

Authors:  Songtao Liu; Qinghua Meng; Yuan Xu; Jianxin Zhou
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-09-25

4.  Design for a Multicentre Prospective Cohort for the Assessment of Platelet Function in Patients with Hepatitis-B-Virus-Related Acute-on-Chronic Liver Failure.

Authors:  Xiuhua Jiang; Shiqi Chai; Yan Huang; Zuxiong Huang; Wenting Tan; Yanhang Gao; Xiaobo Lu; Zhongji Meng; Huayou Zhou; Wenbing Kong; Xiaoting Tang; Yujun Tang; Tingting Qi; Chengjin Liao; Qiaorong Gan; Xiaomei Xiang; Yanan Zhang; Shuai Wang; Yuanyuan Chen; Jinjun Chen
Journal:  Clin Epidemiol       Date:  2022-08-24       Impact factor: 5.814

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.